ArticleLeukemia2026
Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.
Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma progresses from bone marrow-confined disease to systemic forms through processes linked to loss of adhesion and EMT-related programs. We analyzed baseline plasma cell RNA-seq, microarray, and single-cell datasets to derive and validate a dissemination score. In the newly diagnosed MMRF CoMMpass cohort (n = 754), differential expression analyses of circulating plasma cells (n = 592) and PET-CT-confirmed plasmacytomas (n = 118), integrated with 1114 EMTome genes, identified 1357 dissemination-associated genes. Elastic Net Cox regression derived a 30-gene Dissemination Score (DS) that stratified overall survival (54.5 vs 102.5 mo; C-index 0.71) and improved prognostic performance when added to UAMS70 and EMC92 in bootstrap analyses. DS was associated with Adverse stromal interaction (ASI) and stratified high-risk ASI interactions. In an independent Mayo Clinic cohort (n = 133), DS reproduced prognostic discrimination (52.1 vs 113.6 mo, p < 0.01) and predicted earlier dissemination events (2.1 vs 6.8 yrs, p < 0.01). In GSE117156, circulating plasma cells showed consistently higher DS than marrow plasma cells across MGUS, SMM, MM, and AL, with progressive DS increase from controls to MM. In GSE106218, CD138⁺ extramedullary plasma cells had higher DS than marrow plasma cells (p < 0.01). Collectively, DS quantifies dissemination biology.
Indexed as
Identifiers
42020784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.